New England Pediatric Sickle Cell Consortium
presents the
8th Annual Sickle Cell Disease Symposium
October 5th 2017|Beechwood Hotel, Worcester, MA
Artist: Hertz Nazaire. Reproduced with permission.
PROGRAM DESCRIPTION
This program will address issues around the
current management of aspects of sickle cell
anemia (SCA) and future directions in the care of
patients with SCA. It will discuss clinical trials
that are currently available to patients with this
disorder and explore the impact of investigational
trials in this population. Finally it will afford
discussion by involved stakeholders on the
consequences of the national opioid crisis on
individuals with SCD.
LEARNING OBJECTIVES
At the completion of this activity, participants
should be able to:
Discuss current and new approaches to the
management of sickle cell disease and its
complications
Identify current clinical trials as they
impact sickle cell disease
Jointly Provided by
PROGRAM GOAL
The goal of this program is to update providers of
patients with SCA and its related disorders with
details of current and future approaches to the
management of SCA and to discuss clinical trials
available to these patients, putting the trials in the
context of the community being care for. This
program will allow patients with SCA and their
families know more about therapies and clinical
trials currently available for them and will allow
those touched by SCA to discuss the impact of the
current opioid crisis on their care.
TARGET AUDIENCE
Healthcare providers involved in the care and
management of patients with sickle cell anemia and
related disorders.
 8th Annual Sickle Cell Disease Symposium Agenda
9:00-9:50 am Registration, Refreshments and Visit Exhibitors

9:50-10:00 am Welcome Remarks

10:00-10:45 am Stem Cell Transplantation for Sickle Cell Disease

Niketa C. Shah, MD, MBBS
Assistant Professor, Pediatric Hematology-Oncology
Director, Pediatric Bone Marrow Transplant, Yale School of Medicine
Yale New Haven Hospital | New Haven, CT

10:45-11:30 am Gene Therapy for Sickle Cell Disease

Daniel E. Bauer, MD, PhD
Assistant Professor of Pediatrics, Harvard Medical School
Pediatric Hematology-Oncology
Dana-Farber Cancer Institute & Boston Childrens Hospital | Boston, MA

11:30-12:15 pm Clinical Trials for Patients with Sickle Cell Disease

Matthew M. Heeney, MD
Assistant Professor of Pediatrics, Harvard Medical School
Clinical Director, Pediatric Blood Disorders
Associate Chief, Hematology
Director, Sickle Cell Program
Dana-Farber Cancer Institute & Boston Childrens Hospital |Boston, MA

12:15-12:30 pm Q&A on Morning Sessions

12:30-2:00 pm Lunch, Breakout Sessions and Visit Exhibitors

2:00-2:45 pm Chronic Pain Management

Angela C. Anderson, MD, FAAP
Associate Professor of Pediatrics and Emergency Medicine
Warren Alpert Medical School of Brown University
Director, Pediatric Pain and Palliative Care
Hasbro Childrens Hospital | Providence, RI

2:45-3:00 pm Q&A on Pain Management

3:00-4:15 pm Point-Counter-Point: A Discussion on the Opioid Crisis as it Impacts Patients with

Sickle Cell Disease
Moderator: Anjulika Chawla, MD | Associate Professor of Pediatrics, Warren Alpert Medical
School of Brown University
Interim Division Chair, Hasbro Childrens Hospital | Providence, RI

Panelists:
Nicole Alexander-Scott, MD, MPH
Director, Rhode Island Department of Health | Providence, RI
Ingrid Gillespie, BPE MSc in CED
Past President, CT Prevention Network
Executive Director, Communities 4 Action
Member of CT Alcohol & Drug Policy Counsel | Stamford, CT
Tom Sannicandro
Director, Institute for Community Inclusion, School for Global Inclusion and Social
Development
Umass | Boston Massachusetts

4:15-4:30 pm Wrap Up and Feedback

PLANNING COMMITTEE
Heidi Abendroth, RN, BSN, MSN | Massachusetts General Hospital, Boston, Massachusetts
Eileen Hansbury, PA-C | Hasbro Childrens Hospital, Providence, Rhode Island
Philippa Sprinz, MD, MSc | Hasbro Childrens Hospital, Providence, Rhode Island

REGISTRATION FEES
There is no fee to attend this conference: Breakfast and lunch is included.

ACCREDITATION
This activity has been planned and implemented in accordance with the Accreditation Criteria and
Policies of the Rhode Island Medical Society (RIMS) through the joint providership of Rhode Island
Hospital and the New England Pediatric Sickle Cell Consortium. Rhode Island Hospital is accredited by
the Rhode Island Medical Society to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: Rhode Island designates this live activity for a maximum of 5.0 AMA PRA Category
1 credit(s) . Physicians should claim only the credit commensurate with the extent of their participation
in this activity.

Rhode Island Specific: This program qualifies for 2.0 hours CME credit in Risk Management in Opioid
Pain Management/Chronic Pain Management, three of the required areas of section 6.0; 6.2.1 RI CME re-
licensure requirements.

This training meets the requirements set forth in RI Regulation 3.14 Prescriber Training Requirement for
Best Practices Regarding Opioid Prescribing. This specific training requirement is required only once &
must be completed before renewal of controlled substance registration or two (2) years (whichever is
longer).

Physician Assistants/Nurse Practitioners: Participants will receive a certificate of attendance stating this
program is designated for 5.0 AMA PRA Category 1 credit(s) . This credit is accepted by the AAPA and
AANP.

Social Workers: CEs have been applied for.

FOR MORE INFORMATION: Contact:

Heidi Abendroth, HAbendroth@partners.org
Eileen Hansbury, Ehansbury@lifespan.org
Philippa Sprinz, Philippa.Sprinz@lifespan.org

Please notify any member of the planning committee by email at least two weeks
prior to the conference to request reasonable accommodations.

We would like to acknowledge the support of the following